在非小细胞肺癌中新辅助化学免疫疗法的有效性:现实世界,多中心,回顾性研究
Xun Wang1,2, Xin Wang1,2, Bengang Hui3
1Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China.
Translational lung cancer research
|May 13, 2024
概括
新辅助化疗免疫疗法对可切除的非小细胞肺癌 (NSCLC) 显示出前景,提供高率的病理完整反应 (pCR) 和主要病理反应 (MPR). 这种方法改善了生存结果,MPR和pCR可能作为有效的替代终点.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胸部外科手术 胸部外科手术
背景情况:
- 可切除的非小细胞肺癌 (NSCLC) 具有显著的复发风险.
- 新辅助化疗免疫疗法已成为这些患者有前途的治疗策略.
- 现实世界的数据对于评估其安全性和有效性至关重要.
研究的目的:
- 评估新辅助化疗-免疫疗法的安全性和外科治疗结果,用于大量NSCLC患者群体.
- 评估瘤结果,包括病理反应和长期存活率.
- 在现实世界中识别病理反应的预测因子.
主要方法:
- 追溯队列研究包括158名临床阶段IB-IIIBNSCLC患者.
- 患者在两个中国机构接受了新辅助化学免疫疗法.
- 收集和分析了手术和瘤的结果,随访时间中位数为27.1个月.
主要成果:
- 观察到高率的病理完整响应 (pCR,39.2%) 和主要病理响应 (MPR,60.1%).
- 在60.4%的患者中,新辅助治疗减少了手术的复杂性.
- MPR和pCR与改善无进展生存期 (PFS) 和整体生存期 (OS) 有显著的关联.
- 编程死亡连接体1 (PD-L1) 表达是病理反应的唯一预测因素.
结论:
- 新辅助化疗免疫疗法是NSCLC的可行策略,表现出有利的PCR/MPR率,修饰切除和2年生存率.
- 病理反应 (pCR/MPR) 可以作为一种可靠的替代终点,用于治疗新辅助化疗免疫治疗的NSCLC患者的生存.
- 在这个队列中,PD-L1表达是预测病理反应的唯一临床因素.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.1K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
相关概念视频
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...